Analysis of potential drug interactions in pulmonary tuberculosis patients in the pediatric clinic
DOI: https://doi.org/10.56922/mchc.v4i9.2065
Drug interactions; OAT Tuberculosis
Abstract
Background: Analysis of Potential Drug Interactions of Pulmonary Tuberculosis Patients at The Children’s Poly of Imanuel Wayhalim Hospital Bandar Lampung. Tuberculosis (TB) is an infectious disease caused by infection with the bacterium Mycobacterium tuberculosis (MTB). Treatment in tuberculosis patients is given Anti-Tuberculosis Drugs (OAT) consisting of isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin.
Purpose: To analysis of potential drug interactions in pulmonary tuberculosis patients in the pediatric clinic.
Method: This study is a non- experimental descriptive study (observational). Sampling using purposive sampling method. The data collection was retrospectively taken from the medical records of tuberculosis patients at the children's poly of Imanuel Wayhalim Hospital Bandar Lampung for the period October – December 2025.
Results: The results of the study found that the characteristics of TB patients of the highest age were toddlers (0-5 years) as many as 35 patients (83.3%), the highest sex was male as many as 27 cases (64%), potential drug interactions contained in the therapy of TB pediatric patients were pharmacokinetic interactions in the metabolic phase of OAT and OAT as many as 2 cases (50%), pharmaco dynamic interactions of OAT and OAT as many as 2 cases (50%), pharmaco kinetic interactions in the metabolic phase of OAT and other drugs as many as 10 cases (45.5%), pharmacodynamic interactions of OAT and other drugs as many as 12 cases (54.5%). Based on the severity of OAT and OAT drug interactions, Major results were obtained as many as 2 cases (100%) and the severity of OAT drug interactions and other drugs obtained Moderate results as many as 8 cases (57%), Major as many as 6 cases (43%).
Conclusion: Based on research, it can be concluded that anti- tuberculosis drugs that inter actalotarer if ampicin with isoniazid and triamcinolone and the most common type of drug interaction is pharmacokinetics in the metabolic phase. The severity of drug interactions that occur is highest in the moderate category.
Downloads
References
Abdillah, R. Q., & Asmini, P. (2018). Potensi Interaksi Obat pada Pasien Tuberkulosis Rawat Jalan di Rumah Sakit PKU Muhammadiyah Delanggu Tahun 2016 (Doctoral dissertation, Univer
Afrianti, R., Larucy, F., & Widayana, H. (2023). Interaksi Obat Anti Tuberkulosis pada Pasien Tuberkulosis Paru. Jurnal Kesehatan Perintis, 10(1), 53-59.
Baxter, K. (2010). Stockley’s Drug interactions pocket companion 2010. Pharmaceutical Press 2010.
Belang, R. B. (2019). Analisis Terapi Obat Anti Tuberkulosis Pada Pasien Tuberkulosis Di Rumah Sakit Sumber Sentosa Tumpang-Malang (Doctoral dissertation, Akademi Farmasi Putra Indonesia Malang).
Cairns, D. (2009). Intisari Kimia Farmasi Edisi Kedua. Penerjemah: Puspita. Jakarta: Penerbit Buku Kedokteran EGC. Terjemahan dari: Essentials of Pharmaceutical Chemistry.
Chelmow, D., Geibel, J., Grimm, L., Harris, J. E., Maron, D. J., & Meyers, A. D. (2014). Drug Interaction Checker, Medscape.
DiPiro, J. T. (2010). Concepts in clinical pharmacokinetics. ASHP.
Gupta, K. B., Gupta, R., Atreja, A., Verma, M., & Vishvkarma, S. (2009). Tuberculosis and nutrition. Lung India, 26(1), 9-16.
Halima, R. R., Rahimah, S. B., Saefulloh, A., Andriane, Y., & Suherian, E. (2019). Potensi Interaksi Obat Antituberkulosis dan Anti Diabetes terhadap Efek Samping Obat pada Pasien Tuberkulosis-Diabetes Melitus di RSUD Al-Ihsan Bandung. Jurnal Integrasi Kesehatan & Sains, 1(1), 58-61.
Mayasari, S., & Sari, D. A. C. (2025). Profil Potensi Interaksi Obat Pada Pasien Tuberkulosis Fase Intensif Kategori 1 Di Rumah Sakit Paru Jember. Jurnal Ilmiah Farmasi Akademi Farmasi Jember, 8(2), 115-127.
Ministry of Health of the Republic of Indonesia. (2011). DEPKES RI 2011 Pedoman Penanggulangan TB di Indonesia. Retrieved from: https://kupdf.net/download/depkes-ri-2011-pedoman-penanggulangan-tb-di-indonesia-pdf_59f41b82e2b6f5f141312cbe_pdf
Ministry of Health of the Republic of Indonesia. (2014). Kemenkes. 2014. Pedoman Pengendalian Tuberkulosis. Jakarta: Kementrian Kesehatan Republik Indonesia. Retrieved from: https://www.scribd.com/document/326852036/Kemenkes-Ri
Ministry of Health of the Republic of Indonesia. (2019). Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/755/2019 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. Retrieved from: file:///Users/gadis/Downloads/17012248006566a1601671d4.28271429.pdf
Musuenge, B. B., Poda, G. G., & Chen, P. C. (2020). Nutritional status of patients with tuberculosis and associated factors in the health centre region of Burkina Faso. Nutrients, 12(9), 2540.
Piana, W. (2024). Asuhan Keperawatan Bersih Jalan Napas Tidak Efektif Pada Pasien Tuberkulosis Paru Dengan Tindakan Batuk Efektif Di Rsud Dr. Drajat Prawiranegara Serang Banten Tahun 2024 (Doctoral Dissertation, Universitas Sultan Ageng Tirtayasa).
Ramayanti, F., Nurfadhilah, N., Srisantyorini, T., & Ernyasih, E. (2022). Gambaran pelayanan klinik sanitasi pada penyakit ispa dan tuberkulosis di masa pandemi. ENVIRONMENTAL OCCUPATIONAL HEALTH AND SAFETY JOURNAL, 3(1), 11-20.
Suryani, S. (2023). Analisis Profil Pengobatan Dan Potensi Interaksi Obat Pada Pasien Tbc Dewasa di Rs Budi Kemuliaan Jakarta.
Umar, M., Basit, A., Ali, S., & Iqbal, Z. (2022). Understanding the burden: prevalence and predictors of depression and anxiety among multidrug-resistant tuberculosis patients and their household contacts. Pakistan Journal of Chest Medicine, 28(1), 72-79.
Utari, R. D. (2023). Faktor-Faktor Yang Mempengaruhi Ketidakpatuhan Dalam Menjalani Program Pengobatan Pada Klien Tuberkulosis Paru (Doctoral dissertation, Universitas Airlangga).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 THE JOURNAL OF Mother and Child Health Concerns
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
